Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer

Simple item page
dc.contributor.authorShitara, Kohei
dc.contributor.authorAjani, Jaffer A.
dc.contributor.authorMoehler, Markus
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorGallardo, Carlos
dc.contributor.authorShen, Lin
dc.contributor.authorYamaguchi, Kensei
dc.contributor.authorWyrwicz, Lucjan
dc.contributor.authorSkoczylas, Tomasz
dc.contributor.authorBragagnoli, Arinilda Campos
dc.contributor.authorLiu, Tianshu
dc.contributor.authorTehfe, Mustapha
dc.contributor.authorElimova, Elena
dc.contributor.authorBruges, Ricardo
dc.contributor.authorZander, Thomas
dc.contributor.authorde Azevedo, Sergio
dc.contributor.authorKowalyszyn, Ruben
dc.contributor.authorPazo-Cid, Roberto
dc.contributor.authorSchenker, Michael
dc.contributor.authorCleary, James M.
dc.contributor.authorYanez, Patricio
dc.contributor.authorFeeney, Kynan
dc.contributor.authorKaramouzis, Michalis, V
dc.contributor.authorPoulart, Valerie
dc.contributor.authorLei, Ming
dc.contributor.authorXiao, Hong
dc.contributor.authorKondo, Kaoru
dc.contributor.authorLi, Mingshun
dc.contributor.authorJanjigian, Yelena Y.
dc.date.accessioned2025-01-20T21:10:59Z
dc.date.available2025-01-20T21:10:59Z
dc.date.issued2022
dc.description.abstractStandard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma(1-4). Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial(5) (programmed death ligand-1 (PD-L1) combined positive score >= 5 and all randomized patients). On the basis of these results, nivolumab plus chemotherapy is now approved as a first-line treatment for these patients in many countries(6). Nivolumab and the cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor ipilimumab have distinct but complementary mechanisms of action that contribute to the restoration of anti-tumour T-cell function and induction of de novo anti-tumour T-cell responses, respectively(7-)(11). Treatment combining 1 mg kg(-1) nivolumab with 3 mg kg(-1) ipilimumab demonstrated clinically meaningful anti-tumour activity with a manageable safety profile in heavily pre-treated patients with advanced gastro-oesophageal cancer(12). Here we report both long-term follow-up results comparing nivolumab plus chemotherapyversus chemotherapy alone and the first results comparing nivolumab plus ipilimumab versus chemotherapy alone from CheckMate 649. After the 24.0-month minimum follow-up, nivolumab plus chemotherapy continued to demonstrate improvement in overall survival versus chemotherapy alone in patients with PD-L1 combined positive >= 5 score (hazard ratio 0.70; 95% confidence interval 0.61, 0.81) and all randomized patients (hazard ratio 0.79; 95% confidence interval 0.71, 0.88). Overall survival in patients with PD-L1 combined positive score >= 5 for nivolumab plus ipilimumab versus chemotherapy alone did not meet the prespecified boundary for significance. No new safety signals were identified. Our results support the continued use of nivolumab plus chemotherapy as standard first-line treatment for advanced gastro-oesophageal adenocarcinoma.
dc.fuente.origenWOS
dc.identifier.doi10.1038/s41586-022-04508-4
dc.identifier.eissn1476-4687
dc.identifier.issn0028-0836
dc.identifier.urihttps://doi.org/10.1038/s41586-022-04508-4
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/93603
dc.identifier.wosidWOS:000772363100008
dc.issue.numero7903
dc.language.isoen
dc.pagina.final+
dc.pagina.inicio942
dc.revistaNature
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleNivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
dc.typeartículo
dc.volumen603
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas